Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Abeona Therapeutics Inc ABEO

Healthcare Biotechnology
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The... see more

Recent & Breaking News (NDAQ:ABEO)

Abeona Therapeutics, Inc. to Host Earnings Call

Accesswire March 27, 2018

Earnings Scheduled For March 27, 2018

Benzinga.com  March 27, 2018

Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights

GlobeNewswire March 16, 2018

Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease

GlobeNewswire March 15, 2018

Abeona Therapeutics Announces Upcoming Conference Participation

GlobeNewswire February 21, 2018

Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA

GlobeNewswire February 8, 2018

Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial

GlobeNewswire February 7, 2018

Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium

GlobeNewswire February 2, 2018

Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa

GlobeNewswire January 29, 2018

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

PR Newswire January 2, 2018

Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB

GlobeNewswire December 20, 2017

Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights

GlobeNewswire November 15, 2017

Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA

GlobeNewswire November 9, 2017

Biotech Stocks on Investors' Radar -- Synthetic Biologics, 22nd Century, Abeona Therapeutics, and Aeterna Zentaris

PR Newswire October 31, 2017

Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire October 19, 2017

Abeona Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire October 16, 2017

Abeona Therapeutics Announces Public Offering of Common Stock

GlobeNewswire October 16, 2017

4 Biotechs Boosted By Spark Therapeutic's FDA News

Benzinga.com  October 16, 2017

Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies

GlobeNewswire October 16, 2017

Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA

GlobeNewswire October 11, 2017